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Background: Nasal obstruction is a primary symptom of common upper respiratory tract disorders. In clinical
practice nasal saline solutions are recommended for the cleansing of nasal cavities and relieving nasal symptoms.
Methods: 55 patients (aged 25–70 years) suffering from obstructive rhinopathy, with nasal obstruction/congestion
of moderate severity persistent since at least 10 days in advance of recruitment with/without rhinosinusitis was
randomly treated with an hypertonic solution composed by Silver Sucrose Octasulfate and Potassium Sucrose
Octasulfate (SILSOS) or isotonic solution for 20 days.
At baseline (T0), ten days (T10) and twenty days (T20) after SILSOS treatment, study participants were evaluated
subjectively with VAS and SNOT-22, objectively by Active Anterior Rhinomanometry (AAR) and MCC/MCTt
determination. Forty-four patients were followed-up 30 days after the end of treatment by a phone interview.
Results: The AAR analysis showed in SILSOS group a significantly (p < 0.05) ameliorated in expiratory flow, at T0-T10
and T0-T20. No improvement in MCTt was observed over the 20 days study period. The mean values MCC of
significantly improved at T20 (p < 0.05). VAS total score showed improvement along all time-intervals. Nasal
obstruction was back 30 days after the end of treatment with SILSOS in only 3 patients and reported to be in a mild
form.
Conclusions: The obtained results show that SILSOS hyper has added to the mechanical action of removal of
secretions a specific decongestant and antiseptic effect lasting longer after the end of treatment. Could help
to fluidize thick mucus, improve respiration and promote resolution of symptoms, preventing pathogens
adhesion to nasal mucosa.
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The complaint of blockage, fullness, or restricted airflow
are frequent in patients with nasal obstruction. The
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are common condition in cold and acute or chronic
rhinosinusitis with/without nasal polyposis.* Correspondence: d.passali@virgilio.it
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in any medium, provided the original work is pRhinosinusitis are defined as inflammation of the nose
and the paranasal sinuses characterized by two or more
symptoms, one of which should be either nasal blockage
obstruction congestion or nasal discharge (anterior/
posterior nasal drip) ± facial pain/pressure or ± reduction
or loss of smell (Fokkens et al. 2007; Rosenfeld et al. 2007;
Scadding et al. 2008). Anterior Active Rhinomanometric
(AAR) measurement of nasal resistance and nasal peak
flow correlate well with subjective sensation of nasal
obstruction (Fokkens et al. 2012; Passali et al. 2000), al-
though this correlation remain uncertain (Andre et al.n open access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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right, and total Nasal Airflow Resistance (NAR, NARtotal =
NARleft × NARright/NARleft + NARright (Clement 1991)).
A 10-cm Visual Analogic Scale (VAS) was validated
for patients with rhinosinusitis and divided the severity
of disease into mild (VAS 0–3), moderate (VAS >3-7)
and severe (VAS >7-10) (Fokkens et al. 2007; Scadding
et al. 2008; Fokkens et al. 2012). A VAS > 5 affects pa-
tients Quality of Life (QOL) (Lim et al. 2007).
Sino-Nasal Outcome Tests (SNOT-22) (Hopkins et al.
2009) was an health related quality of life instrument
for chronic rhinosinusitis and range from 0 (absence of
symptoms) to 5 (the highest severity degree).
Mucociliary clearance (MCC) and/or the mucociliary
transport time (MCTt) are involved in the defensive mech-
anisms against paranasal sinuses infection, in patients with
rhinosinusitis assume pathological values due transudation
that thickening the periciliary layer (Antunes et al. 2009;
Cohen 2006; Passali 2003; Jones 2001).
MCC and MCTt were determined by means of the
charcoal + 3% saccharine test. The insoluble charcoal
powder determinate the transport of foreign bodies like
bacteria or dust particles entrapped into the outer
mucus layer, the soluble saccharine measure the clear-
ance (i.e. the dilution and drainage) of solutes into the
inner mucus layer. The patient’s perception of the sweet
saccharine taste and the black color of charcoal in phar-
ynx are easily detectable. MCC/MCTt is reported to take
more than 30 minutes in pathological conditions; MCTt
normal values are 13 ± 2 minutes in adults; MCC normal
values are 17 ± 5 minutes in adults (Passali et al. 1984).
Endoscopic signs of rhinosinusitis are polyps and/or
mucopurulent discharge primarily from middle meatus
and/or oedema/mucosal obstruction primarily in middle
meatus, that promote stasis of secretions and prolifera-
tion of bacteria to on sinonasal mucosa, bringing to an
inflammatory mucosal response, worsening sinonasal
symptoms and facilitating onset and/or recurrence of in-
fections. Consequently, the solubilisation and release of
secretions represent a basis of symptom resolution and
functional improvement. Isotonic and hypertonic saline
nasal wash/irrigation are an effective intervention, ad-
junct or not to medical therapy, to determinate MCC/
MCTt recovery, reduce nasal mucosal edema, and make
easy the elimination of microorganisms and secretions
(Harvey et al. 2007; Thomas et al. 2008; Süslü et al.
2009; Talbot et al. 1997).
In patients with acute upper respiratory tract infec-
tions saline nasal irrigation is associated with less time
off work and with a tendency towards less antibiotic
usage (Kassel et al. 2010).
SILSOS hyper, CM&D Pharma Limited is a Medical
Device (MD) composed by the association of Silver
Sucrose Octasulfate (IASOS; US7183315, EP1458733)and Potassium Sucrose Octasulfate (KSOS). Combining the
antimicrobial property of IASOS and the carbohydrate-
based microbial antiadhesion of KSOS, SILSOS hyper
restore nasal mucosae, reinforce the tropism through
Fibroblast Growth Factor pathway activation and facilitate
mucosal decongestion and hydration (Rashid et al. 1999;
Yeh et al. 2002).
The main aim of this study was to valuated the efficacy
of a 20 days period of treatment with MD on MCC and
MCTt values compared to the simple treatment with
isotonic solution. Valuate usefulness on primary and sec-
ondary symptoms of rhinosinusitis using visual analog
scale (VAS) and Sino-Nasal Outcome Tests (SNOT-22)
in patients with nasal respiratory obstruction.
Methods
Between February 2012 and February 2013, 55 consecu-
tive patients (aged 25–70, 20 male) with obstructive rhino-
pathy of various aetiology were seen in our Department.
Inclusion criteria was have persistent symptoms since at
least 10 days in advance of recruitment due to inferior tur-
binate hypertrophy or congestion associated at a pre-
existing deviated nasal septum, VAS > 5 for two of the pri-
mary symptoms: nasal congestion, nasal obstruction and
Rhinorrea or VAS > 5 for one of the primary symptoms
above and VAS >3 for at least one of the secondary symp-
toms: facial pain/pressure, reduction or loss of smell. Ex-
clusion criteria were pregnancy, persistent/intermittent
allergic rhinitis, cystic fibrosis, gross immunodeficiency
(congenital or acquired), congenital mucociliary problems,
fungal disease, systemic vasculitis and granulomatous
diseases, cocaine abuse, diagnosis of nasal polyps (Lund/
McKay II-III degree), nasal neoplasia; participation in
other clinical trials within 3 months from enrolment;
treatment with local and/or systemic corticosteroid, anti-
biotic, decongestants and nasal saline washes within one
week from enrolment.
The patients were randomly assigned by a computer-
generated eight blocks code to treatment by isotinic so-
lution (n = 30) or MD treatment (n = 25).
Participants were evaluated subjectively with VAS and
SNOT-22, and objectively with AAR, MCC and MCTt
at baseline (T0), ten days (T10) and twenty days (T20)
after MD treatment (2 sprays/nostril, two times a day for
20 days).
To assess compliance, the dispenser weight at T0 and
at T20 were recorded.
All the patients were followed-up after 30 days the end
of the treatment with a phone interview aimed to evalu-
ate the long term effectiveness of the treatment.
After receiving detailed information about study aim,
all participants signed their Informed Consent in com-
pliance with the Declaration of Helsinki and current
Good Clinical Practice. The study protocol was approved
Table 2 MCTt and MCC at T0, T10 and T20 days after









T0 13.0 ± 1.10 Vs T10 > 0.05 20.20 ± 4.38 Vs T10 > 0.05
Vs T20 > 0.05 Vs T20 < 0.05*
T10 12.64 ± 0.81 Vs T20 > 0.05 17.96 ± 4.23 Vs T20 > 0.05
T20 12.72 ± 0.84 / 16.08 ± 4.24 /
*p < 0.05 T0 versus T20, Friedman test.
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“Le Scotte”, Siena (Nr 93/2011, November 22, 2011).
ANOVA was performed on continuous variables and
categorical variables. Kruskal-Wallis were applied as
appropriate for significance between treatment groups
(Saline vs MD). Comparisons between groups were
assessed by the Wilcoxon Signed Rank Test (significance
of changes in secondary endpoints at different time inter-
vals) or Friedman Test or t-test, as appropriate, at a signifi-
cance level of p < 0.05. Statistical analysis was performed
with SPSS software (SPSS, Inc., Chicago, IL, USA).
Results
Twenty patients had acute rhinosinusitis at the begin-
ning of the therapy with MD, these patients have associ-
ated at the nasal irrigation an antibiotic therapy (500 mg/
die of fluoroquinolone drug class) for 14 days.
Controls of dispenser’s weight does not have shown a
lack of compliance by patients who have received treat-
ment with MD while in 5 patients in the saline solution
group there was a remaining weight more than 25% of
the total at T1examination and therefore these patients
were excluded from the study and from results.
AAR analysis were reported in Table 1, at baseline
total NAR were more than doubled the healthy 0,25 Pa/
ml/s reported value (Clement 1991). MD progressively
and significantly (p < 0.05, Wilcoxon signed rank test)
ameliorated in expiratory flow, both at T0-T10 and T0-
T20. No significantly variation was observed in control
group.
Table 2 report MCTt and MCC values at baseline, and
after ten (T10) and twenty (T20) days of treatment. The
mean value of MCTt at T0 was normal while MCC
times were at the upper limits of the normal range. No
significant improvement in MCTt was observed over the
20 day study period, or at T0-T10 and T10-T20 time-
points. The mean MCC values significantly improved at
T20 (p = 0.0003, Friedman test), the ΔT0-T20 was
4.12 minutes. These differences have to be considered
clinically significant. No significantly variation was ob-
served in control group.
Table 3 reports VAS total score (mean ± SD) for pri-
mary, primary plus secondary symptoms, and the VAS
Mean Score (mean ± SD), defined as: total symptomsTable 1 AAR. Total nasal resistance at different
timepoints
MD - Total resistance (Pa/ml/s)
Time Inspiratory flow Expiratory flow
T0 0.660 ± 0.601 0.662 ± 0.579
T10 0.510 ± 0.427 0.470 ± 0.327*
T20 0.420 ± 0.218 0.382 ± 0.205*
*p < 0.05 versus T0, Wilcoxon signed rank test.score/n. symptoms, and expressing the severity of the
reported symptoms. On the overall treatment period
(T0-T20), MD improved VAS total score for primary,
primary and secondary symptoms, and VAS mean score
(p < 0.05 vs T0). For primary and secondary symptoms
MD showed a VAS total improvement along all time-
intervals (p < 0.05). In general, the MD demonstrated to
be as effective on MCC times and better scores in pri-
mary, primary and secondary symptoms, and their severity
degree at T0-T20. Similar variation in VAS total score
(mean ± SD) for primary, primary plus secondary symp-
toms, and the VAS Mean Score was reported at T20 in
isotonic control group.
Table 4 reported the effects of MD on the SNOT-22
scores, after twenty days of use an improvement in nasal
obstruction/congestion, posterior nasal discharge and
thick nasal discharge items was observed with an im-
provement in productivity and concentration items. In
control group was detected an improvement in total
SNOT-22 scores, in nasal obstruction/congestion item
and in posterior nasal discharge.
MD effect on nasal obstruction/congestion and nasal
discharge, being these symptoms of relevance in the clin-
ical diagnosis of rhinosinusitis, were also considered in the
small, good balanced subgroup of rhinosinusitis patients.
Results are summarized in Figure 1.
All data about the control group was reported in
Table 5.
44/50 patients carried the follow up-interview, 30 days
after treatment, only 3/22 patients of MD group reported
the presence of subjective nasal obstruction, which was
graded as a mild form. In control group 10/22 patients
after 30 days reported the presence of subjective nasal
obstruction.
Discussion
In our study population, nasal obstruction was the most
relevant patients’ disorder as well as a major inclusion
criteria to enrollment. After treatment, the more salient
effect observed was the significantly decreased scoring
for nasal obstruction/congestion on the overall treatment
period. The symptom relief resulted to depend upon
amelioration of posterior nasal discharge, thick discharge
and ear fullness. These parameters suggest a success in
Table 3 VAS Total and Mean Score (mean ± SD) at different timepoints in the two study groups
Primary symptoms Primary + secondary symptoms Total score/n symptoms
VAS total score VAS total score VAS mean score
P (Friedman test) P (Friedman test) P (RM ANOVA)
T0 11,5 ± 3,4 Vs T10 < 0.05* 15.6 ± 3.7 Vs T10 < 0.05* 5,7 ± 1,5 Vs T10 > 0.05
Vs T20 < 0.001** Vs T20 < 0.001** Vs T20 < 0.05°
T10 9,6 ± 3,1 Vs T20 > 0.05 12.8 ± 3.5 Vs T20 < 0.05°° 4,9 ± 1,3 Vs T20 > 0.05
T20 7,6 ± 2,8 10.5 ± 4.0 4,0 ± 1,3
*p < 0.05 T0 versus T10, Friedman test; **p < 0.001 T0 versus T20, Friedman test; °p < 0.05 T0 versus T20, Repeated Measures ANOVA; °°p < 0.05 T10 versus T20,
Friedman test.
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ery on health-related quality of life.
Although subjective assessment of nasal obstruction
by patient-reported outcome measurements (PROMs) is
a well-validated criterion, if little correlation were found
between a patient-based symptom severity-scoring sys-
tems and an objective respiratory parameter, the impact
of symptom amelioration could be overestimated. In our
patients, a good matching of ameliorated PROMs andTable 4 Effect of the MD on the SNOT-22 Scores (Median valu
ITEMS
T0
Need to blow the nose 2,12 ± 1,0 (2)
Sneezing 1,40 ± 1,2 (1)
Runny nose 2,00 ± 1,6 (2)
Cough 0,76 ± 1,0 (0)
Posterior nasal discharge 1,68 ± 1,5 (1)
Thick nasal discharge 1,28 ± 1,1 (1)
Ear fullness 1,40 ± 1,0 (1)
Dizziness ——————————
Ear pain 0,12 ± 0,4 (0)
Facial pain/pressure 1,12 ± 1,5 (1)
Difficulty falling asleep 1,80 ± 1,5 (2)
Waking up at night 1,90 ± 1,3 (2)
Lack of a good night sleep 2,10 ± 1,4 (2)
Waking up tired 2,00 ± 1,4 (2)
Fatigue 1,90 ± 1,4 (2)
Reduced productivity 0,80 ± 1,1 (1)
Reduced concentration 1,20 ± 1,0 (1)
Frustrated/restless/irritable 0,60 ± 1,0 (0)
Sad 0,04 ± 0,2 (0)
Embarrassed 0,04 ± 0,2 (0)
Sense of smell/taste 1,48 ±1,6 (1)
Nasal obstruction/congestion 4,64 ± 0,5 (4)
TOTAL SCORE 30,0 ± 9,7 (28)
T20 Vs T0 : *p < 0,05 **p < 0.001; T20 Vs T10 : °p < 0,05, Δp < 0. 005 (Wilcoxon Test).total nasal resistance was observed at T20, indicating an
improved respiration.
Subjective improvement that was observed in the VAS
scores and in SNOT 22 scores both in subjects treated
with MD than in control group was not confirmed by
the rhinometry data that showed an objective statistically
significant improvement only in the MD group.
Rhinomanometry has been reported to correlate with
subjective symptom scoring with and without decongestiones)
MD
T10 T20
2,28 ± 1,0 (2) 2,04 ± 1,0 (2)
1,08 ± 0,9 (1) 0,88 ± 0,9 (1)
2,00 ± 1,5 (2) 2,00 ± 1,3 (2)
0,52 ± 0,8 (0) 0,44 ± 0,9 (0)
1,16 ± 1,1 (1) 0,60 ± 0,8* (1)
0,72 ± 0,7 (1) 0,56 ± 0,8* (1)
1,20 ± 0,7 (1) 0,92 ± 0,5* (1)
—————————— ——————————
0,08 ± 0,3 (0) 0,00 ± 0,0 (0)
0,84 ± 1,3 (1) 0,76 ± 1,2 (1)
1,60 ± 1,3 (2) 1,60 ± 1,3 (2)
1,40 ± 1,2 (1) 1,40 ± 1,2 (1)
1,60 ± 1,3 (2) 1,60 ± 1,2 (2)
1,80 ± 1,1 (2) 1,80 ± 1,2 (2)
1,70 ± 1,2 (2) 1,40 ± 1,3 (2)
0,64 ± 1,1 (0) 0,16 ± 0,5**° (0)
0,64 ± 1,0* (1) 0,40 ± 0,9** (0)
0,36 ± 0,9 (0) 0,40 ± 1,1 (0)
0,04 ± 0,2 (0) 0,12 ± 0,6 (0)
0,08 ± 0,3 (0) 0,12 ± 0,6 (0)
0,88 ± 1,4 (1) 0,68 ± 1,2 (0)
3,72 ± 0,8** (3) 2,96 ± 0,9**Δ (3)
24,2 ± 8,4* (24) 20,8 ± 8,7** (21)
Figure 1 SNOT-22, VAS Primary Simptoms and VAS Primary + Secondary Simptoms variation at T10 and T20. On the overall treatment
period (T0-T20), MD improved VAS total score for primary, primary + secondary symptoms, and SNOT-22 mean score (p < 0.05 vs T0).
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sidering studies with normal controls, patients with struc-
tural abnormalities, hyper-reactivity or infective rhinitis,
between the subjective sensation of nasal obstruction and
AAR values (Fairley et al. 1993; Sipilä et al. 1994; Simola
and Malmberg 1997; Hirschberg and Rezek 1998; Nummi-
nen et al. 2003; Nathan et al. 2005). Even if some reports
did not validate these data (Jones et al. 1989) or showed
weak associations between PROMs and rhinomanometry
(Eccles and Jones 1983; Roithmann et al. 1994; Panagou
et al. 1998), does not necessarily imply that either subjective
or objective scores are invalid, because these two ap-
proaches measure different aspects of the disease process.
Subjective nasal obstruction correlates better with objectiveTable 5 Control group data
Isotonic solution T0
Inspiratory flow (Pa/ml/s) 0.533 ± 0.439
Expiratory flow (Pa/ml/s) 0.542 ± 0.435
MCTt (minutes) 13.0 ± 1.3
MCC (minutes) 21.52 ± 4.593
Primary symptoms 11,2 ± 3,7
Primary + secondary symptoms 15.5 ± 4.5
VAS Mean score 5,6 ± 1,7
SNOT-22 Total score 33,0 ± 12,0
*T0 Vs T10 < 0.05 ; **T0 Vs T20 < 0.05.functional measurements of nasal airflow resistance (rhino-
manometry, peak flow) than with measurements of nasal
cavity width, such as acoustic rhinometry (Numminen et al.
2003; Szücs and Clement 1998). The measurement of nasal
airway resistance by assessing nasal flow at a constant pres-
sure can be useful in confirming that improvement in nasal
congestion is the result of reduction in inflammation in the
middle meatus rather than mechanical obstruction.
There is a limitation in main aim of the study because
upon inclusion, patients had normal MCTt values and
MCC times were at the upper limits of the normal
range. Hence, no large improvements could be expected
from a one to two week course of treatment. Consider-
ing these baseline values, the observed improvement inT10 T20
0.507 ± 0.336 0.486 ± 0.207
0.502 ± 0.285 0.475 ± 0.212
12.88 ± 0.78 12.84 ± 0.86
19.68 ± 4.498 19.60 ± 5.480
8,6 ± 2,7* 7,1 ± 3,2**
12.4 ± 4.0* 10.5 ± 4.1**
4,7 ± 1,3 4,0 ± 1,5**
26,0 ± 10,0* 22,0 ± 11,0**
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The greater success of the MD on the MCC times could
depend on its hyper osmolarity. Hypertonic solutions
are more helpful than isotonic solution since the drain-
age of the solutes into the inner “sol” layer can benefit of
the dilution induced by the osmotic effect (Rashid et al.
1999). MCTt is expression of the equilibrium between
both the inner “sol” layer and the outer “gel” layer and
therefore, it needs prolonged or repeated treatments be-
fore a change could be appreciated.
An interesting findings comes from self-reported recur-
rences at follow-up. Nasal obstruction was back 30 days
after the end of treatment in only 3 patients, and reported
to be in a mild form. MD has the mechanical action of re-
moval secretions, a specific decongestant and antiseptic
effect lasting longer after the end of treatment.
MD could help to fluidize thick mucus, improve res-
piration and promote resolution of symptoms, in view of
its natural decongestant activity and of its hydrating ef-
fects. MD were very well tolerated by patients since no
adverse effect or complaints was recorded during the
study, compliance was 78%.
The absence of Sodium Chloride in MD exclude the
burning and bleeding events, sometime referred for
nasal physiological solutions. The new MD seems to rep-
resent a secure alternative to present nasal salty prepara-
tions, alone or in adjunct to the medical therapy, with
the advantage of a superior symptom relief.
Conclusions
This paper describes the results obtained by patients
with acute upper respiratory tract infections or obstruct-
ive rhinopathy from nasal irrigation with SILSOS hyper.
At the mechanical action of removal secretions adds a
specific decongestant and antiseptic effect lasting longer
after the end of treatment which result in an improve-
ment in PROMs like VAS and SNOT-22. Could help to
fluidize thick mucus, improve respiration and promote
resolution of symptoms, preventing pathogens adhesion
to nasal mucosa.
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